geldanamycin has been researched along with celastrol* in 2 studies
2 other study(ies) available for geldanamycin and celastrol
Article | Year |
---|---|
A systematic protocol for the characterization of Hsp90 modulators.
Several Hsp90 modulators have been identified including the N-terminal ligand geldanamycin (GDA), the C-terminal ligand novobiocin (NB), and the co-chaperone disruptor celastrol. Other Hsp90 modulators elicit a mechanism of action that remains unknown. For example, the natural product gedunin and the synthetic anti-spermatogenic agent H2-gamendazole, recently identified Hsp90 modulators, manifest biological activity through undefined mechanisms. Herein, we report a series of biochemical techniques used to classify such modulators into identifiable categories. Such studies provided evidence that gedunin and H2-gamendazole both modulate Hsp90 via a mechanism similar to celastrol, and unlike NB or GDA. Topics: Benzoquinones; Cell Line, Tumor; Chromatography, Affinity; HSP90 Heat-Shock Proteins; Humans; Hydrolysis; Immunoprecipitation; Lactams, Macrocyclic; Models, Molecular; Novobiocin; Pentacyclic Triterpenes; Triterpenes | 2011 |
Gambogic acid, a natural product inhibitor of Hsp90.
A high-throughput screening of natural product libraries identified (-)-gambogic acid (1), a component of the exudate of Garcinia harburyi, as a potential Hsp90 inhibitor, in addition to the known Hsp90 inhibitor celastrol (2). Subsequent testing established that 1 inhibited cell proliferation, brought about the degradation of Hsp90 client proteins in cultured cells, and induced the expression of Hsp70 and Hsp90, which are hallmarks of Hsp90 inhibition. Gambogic acid also disrupted the interaction of Hsp90, Hsp70, and Cdc37 with the heme-regulated eIF2α kinase (HRI, an Hsp90-dependent client) and blocked the maturation of HRI in vitro. Surface plasmon resonance spectroscopy indicated that 1 bound to the N-terminal domain of Hsp90 with a low micromolar Kd, in a manner that was not competitive with the Hsp90 inhibitor geldanamycin (3). Molecular docking experiments supported the posit that 1 binds Hsp90 at a site distinct from Hsp90s ATP binding pocket. The data obtained have firmly established 1 as a novel Hsp90 inhibitor and have provided evidence of a new site that can be targeted for the development of improved Hsp90 inhibitors. Topics: Benzoquinones; Biological Products; Cell Cycle Proteins; Chaperonins; Crystallography, X-Ray; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Pentacyclic Triterpenes; Protein Conformation; Stereoisomerism; Triterpenes; Xanthones | 2011 |